Home LiteratureArticle Details
PMID: 17912073 Published · ppublish English Journal Article Multicenter Study

Multicenter study of wound healing in neurofibromatosis and neurofibroma.

The Journal of craniofacial surgery ·Vol. 18 ·No. 5 ·2007-09-00 ·页码 1008-11

Miyawaki T, Billings B, Har-Shai Y, Agbenorku P, Kokuba E, Moreira-Gonzalez A, Tsukuno M, Kurihara K, Jackson IT

Abstract

Based on clinical experience, the senior author has become convinced that wounds produced to correct the deformities of patients with neurofibromatosis (NF-1) have produced remarkably good scars, the interesting feature being that progression to keloid or hypertrophic scar is rare. The other point noted was that this situation did not change, no matter the patient's race or skin color. There have been few reports describing or discussing this hypothesis. The purpose of this study was to investigate whether wounds produced in the patients with NF-1 produce keloid or hypertrophic scars. The patients with solitary neurofibroma were also included in this study; these were compared with the NF-1 group. This was conducted as a multicenter study. Patients with neurofibromatosis/solitary neurofibroma, who were operated on from 1990 to 2000, were evaluated by reviewing their medical charts and photographs retrospectively. The patients were treated in centers from five different countries. The analysis was undertaken based on the following points: 1) age and sex at surgery; 2) race of the patients; 3) past and family histories of hypertrophic scar and keloid; 4) surgical site(s); 5) diagnosis, NF1 or solitary neurofibroma; 6) surgical complications; 7) number of reoperations to manage the complications; 8) adjuvant therapy for the tumor; 9) depth of the tumors; and 10) incidence of malignant degeneration. A total of 101 cases with neurofibromatosis or solitary neurofibroma was analyzed. The age at surgery ranged from 1 year 6 months to 74 years; sex ratio was 47 males and 54 females. The racial distribution of the patients was 13 white, 13 black, 3 Hispanic, and 58 Asian. There was no past or family history of hypertrophic scar or keloid. The surgical sites were head and neck in 70 cases, trunk in 20 cases, upper extremities in 22 cases, and lower extremities in 20 cases. The clinical diagnosis was NF-1 in 57 cases, solitary neurofibroma in 35 cases, plexiform neurofibroma in four cases, and no distinct clinical diagnosis in five cases. There were no other types of neurofibromatosis. Hematoma and white wide scar were the main postoperative complications found in six cases of NF-1. Infection was also noted in four cases. However, no patient developed hypertrophic scar or keloid in the neurofibromatosis group, whereas two cases showed hypertrophic scar in the solitary neurofibroma group. The outcome showed that the patients with NF-1 and plexiform neurofibroma, no matter the racial group, produce good scars without keloid or hypertrophic changes, whereas solitary neurofibroma has a potential to cause hypertrophic scar.

MeSH 主题词
Adolescent Adult Aged Child Child, Preschool Female Humans Infant Keloid/epidemiology,ethnology,etiology Male Middle Aged Neurofibroma/surgery Neurofibromatoses/surgery Postoperative Complications/epidemiology Racial Groups Retrospective Studies Wound Healing
作者与单位
共 9 位作者,点击展开单位 / ORCID
Miyawaki Takeshi
Institute for Craniofacial and Reconstructive Surgery, Affiliated with Providence Hospital, Southfield, Michigan 48075, USA.
Billings Brian
Har-Shai Yaron
Agbenorku Pius
Kokuba Elisa
Moreira-Gonzalez Andrea
Tsukuno Mari
Kurihara Kunihiro
Jackson Ian T
Article Info
Journal
The Journal of craniofacial surgery
Abbr.
J Craniofac Surg
ISSN
1049-2275
Published
2007-09-00
页码
1008-11
Language
English
Country/Region
United States
NLM ID
9010410
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com